Search ASX code:
Generic filters

Mesoblast’s (ASX:MSB) good COVID-19 news

Mesoblast Limited (ASX: MSB) shares dropped 3% on Friday after announcing news relating to COVID-19 patients.

COVID-19 news

Mesoblast announced that the independent Data Safety Monitoring Board (DSMB) recommended continuation of the phase 3 trial of remestemcel-L in patients with moderate to severe acute respiratory distress syndrome (ARDS) due to a COVID-19 infection, after completion of the trial’s first interim analysis.

The analysis was performed on the first 30% of the total target of randomised patients, with the DSMB reviewing the trial’s primary endpoint, mortality within 30 days of randomisation and all safety data.

Mesoblast chief medical officer Dr Fred Grossman said: “We are very pleased with the recommendation by the DSMB. This important trial seeks to confirm whether remestemcel-L improves survival in ventilated COVID-19 patients with moderate to severe ARDS, where death rates remain high despite best existing treatments.”

The trial is expected to complete recruitment during the fourth quarter of the 2020 calendar year.

Summary

No bad news is good news, I suppose. Mesoblast is one of those biotechs that could produce good returns if things go well, and do poorly if the process doesn’t go well. It’s not the type of investing I like to make, though I can appreciate that Mesoblast could make good returns. If I had to go for a biotech business I’d rather go for CSL Limited (ASX: CSL). However, other ASX growth shares attract me more like Pushpay Holdings Ltd (ASX: PPH).

Free: Our Ultimate BNPL Sector Report

Afterpay, Zip Co, Sezzle… is BNPL the opportunity of a lifetime? Or is the sector a ticking time bomb? Our analyst’s 7,500-word report, Our Ultimate BNPL Sector Report, takes a deep dive into the BNPL sector and shines a spotlight on each of the major players in this booming market. You can get the full report right now (for FREE) by entering your email below, we’ll email it to you.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Free: Our Ultimate BNPL Sector Report

Afterpay, Zip Co, Sezzle… is BNPL the opportunity of a lifetime? Or is the sector a ticking time bomb? Our analyst’s 7,500-word report, Our Ultimate BNPL Sector Report, takes a deep dive into the BNPL sector and shines a spotlight on each of the major players in this booming market. You can get the full report right now (for FREE) by clicking the button below.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading:

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.